Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07795164 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH

Name: Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH — clinical trial record (NCT07795164)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: PERFORMA

StatusRecruiting

PhasePhase 3

SponsorAltimmune, Inc.

Started2026-07-30

View on ClinicalTrials.gov ↗

Phase 3, multicenter, multinational, 2-cohort, randomized, double-blind, placebo controlled, parallel-group pivotal study to evaluate the efficacy, safety, and clinical outcomes of pemvidutide treatment in subjects with noncirrhotic (F2 or F3) metabolic dysfunction-associated steatohepatitis (MASH). Participants will be assigned either to Cohort 1 based on screening histologic (liver biopsy) criteria or to Cohort 2 based on non-invasive test criteria.

Trial Details

NCT Number	NCT07795164
Lead Sponsor	Altimmune, Inc.
Conditions	Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Enrollment	1,800 participants
Start Date	2026-07-30
Primary Completion	2028-12 (estimated)
Study Completion	2032-12 (estimated)
Updated on ClinicalTrials.gov	2026-08-31